United Press International

Alnylam Pharmaceuticals is a biopharmaceutical company. The company develops novel therapeutics based on the biological breakthrough known as ribonucleic acid interference. The company applies ribonucleic acid interference to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies. This discovery enables the creation of a broad new class of human therapeutics. Alnylam Pharmaceuticals maintains partnerships with leading pharmaceutical and medical technology companies to drive further developments and capabilities. Major alliances include Merck, Medtronic and Novartis. Alnylam Pharmaceuticals, founded in 2002, maintains global headquarters in Cambridge, Mass., and has an additional operating unit in Kulmbach, Germany.

TravMedia is the travel industry's only global media network, established in 1999, that connects over 45,000 travel professionals, including 25,000 editors and journalists worldwide. The platform serves as a comprehensive solution for PR professionals and media, facilitating the distribution of press releases, story ideas, and collaborative opportunities across the industry. With operations in nine countries, TravMedia provides essential tools such as Daily News Alerts, Journalist Alerts, and networking capabilities, enabling users to stay updated on the latest trends and build lasting relationships. Its services are trusted by notable brands and play a critical role in enhancing media outreach for travel-related content. Generated from the website